Reevaluating goals of insulin therapy: perspectives from large clinical trials

Endocrinology and Metabolism Clinics of North America
Matthew C Riddle, Kevin C J Yuen

Abstract

Recent large clinical trials have shown that intensive glycemic control can reduce microvascular complications, but appropriate and safe glycemic goals to improve macrovascular outcomes in patients with type 2 diabetes remain poorly defined. This article surveys recent epidemiologic studies and interventional trials, examines the current understanding of the natural history of type 2 diabetes, and proposes new goals and tactics for optimizing insulin therapy.

References

Jul 1, 1992·Diabetes Care·M I HarrisM W Knuiman
Oct 1, 1989·The Journal of Clinical Endocrinology and Metabolism·K R FeingoldM D Siperstein
Feb 14, 1980·The New England Journal of Medicine·J R Williamson, C Kilo
Oct 6, 1997·Endocrinology and Metabolism Clinics of North America·M C Riddle
Apr 28, 2004·Diabetes Care·Edmond A RyanClarissa Wallace
Jun 29, 2004·Diabetes Care·Jonathan B BrownAndrew Perry
Sep 30, 2005·Diabetologia·S FourlanosL C Harrison
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Jul 12, 2007·The American Journal of Cardiology·Hertzel C GersteinUNKNOWN ACCORD Study Group
Feb 15, 2008·Diabetes Care·Zvonko MilicevicMarkolf Hanefeld
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Feb 4, 2009·Circulation·Joohon SungDebbie A Lawlor
Apr 21, 2009·The American Journal of Medicine·Bernard M Y CheungKaren S L Lam
Apr 30, 2009·Diabetes Care·Sharon SaydahEdward Gregg
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Jul 1, 2010·The New England Journal of Medicine·UNKNOWN ACCORD Study GroupLawrence J Fine
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Mar 4, 2011·The New England Journal of Medicine·Hertzel C GersteinWilliam T Friedewald
Apr 20, 2011·Annals of Internal Medicine·Faramarz Ismail-BeigiSaul Genuth
Jan 4, 2012·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Nov 16, 2013·Diabetes Technology & Therapeutics·Markolf HanefeldPeter Bramlage
Jun 29, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Phuong Thanh LeAmbika P Ashraf

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.